EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Where does ISAC (immune-stimulating antibody conjugates) go from here?

Chen Fu

Journal for ImmunoTherapy of Cancer · 2025-08 · 13 (8) · e012500

DOI: 10.1136/jitc-2025-012500 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 25.08.2025. Verfasst von Chen Fu. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning, China cfu@cmu.edu.cn. Hauptthemen laut MEDLINE: Immunoconjugates, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune-stimulating antibody conjugates (ISACs) have emerged as a promising class of therapeutics, employing design principles similar to antibody-drug conjugates (ADCs) but replacing cytotoxic payloads with immune-stimulatory agents. These agents enhance immune system activation, enabling more effective tumor targeting and elimination. However, recent clinical setbacks since 2021 have raised concerns about ISACs’ viability as ADC successors. Although ISAC development remains early-stage, clinical trials have revealed significant challenges, including limited efficacy, systemic toxicity (eg, cytokine release syndrome), and anti-drug antibody generation. Current strategies to overcome these hurdles focus on optimizing payload selection (eg, toll-like receptor 7(TLR7) vs stimulator of interferon genes (STING) agonists), improving linker stability, and exploring localized delivery methods. While ISACs face substantial translational barriers, their potential to synergize with existing immunotherapies and treat “cold” tumors maintains therapeutic promise. Further refinement of design parameters may ultimately position ISACs as a transformative oncology modality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesNeoplasmsImmunotherapyHumansAnimals

Stichwörter der Autor:innen

Antibody-drug conjugates - ADCImmune modulatoryImmunotherapyTumor microenvironment - TME

Substanzen

Immunoconjugates

Autor:innen und Institutionen

  • Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning, China cfu@cmu.edu.cn.
  • Pharmaceutical Sciences Laboratory Center, School of Pharmacy, China Medical University, Shenyang, Liaoning, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Fu, C. (2025). Where does ISAC (immune-stimulating antibody conjugates) go from here?. Journal for ImmunoTherapy of Cancer, 13(8), e012500. https://doi.org/10.1136/jitc-2025-012500

Vancouver

Fu C. Where does ISAC (immune-stimulating antibody conjugates) go from here?. Journal for ImmunoTherapy of Cancer. 2025;13(8):e012500. doi:10.1136/jitc-2025-012500

BibTeX
@article{Fu2025,
  author = {Fu, Chen},
  title = {Where does ISAC (immune-stimulating antibody conjugates) go from here?},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {8},
  pages = {e012500},
  doi = {10.1136/jitc-2025-012500}
}
Kostenlos starten →